Page 215 - 2022_02-Haematologica-web

Letters to the Editor
anti-SARS-CoV-2 vaccines could have a better antibody response than those with MM.11 Anyway, in patients with MGUS, as in those with MM, full vaccination against SARS-CoV-2 should be strongly recommended to reduce the possibility of infection rate and severity of the illness.12-14 Last, but not least, the psychosocial impact of the pandemic on MGUS patients and their management in the long term follow-up also would war- rant to be further and specifically investigated.15
Nicola Sgherza,1 Paola Curci,1 Rita Rizzi,1,2 Vanda Strafella,2 Daniela Di Gennaro,2 Angelantonio Vitucci,1 Antonio Palma,1 Antonella Vita Russo Rossi,1 Francesco Albano,2 Pasquale Stefanizzi,3 Silvio Tafuri3 and Pellegrino Musto1,2
1Hematology and Bone Marrow Transplantation Unit, AOUC Policlinico di Bari; 2Department of Emergency and Organ Transplantation, “Aldo Moro” University School of Medicine and 3Department of Biomedical Science and Human Oncology, “Aldo Moro” University School of Medicine, Bari, Italy
Correspondence:
PELLEGRINO MUSTO- pellegrino.musto@uniba.it doi:10.3324/haematol.2021.279895
Received: September 1, 2021.
Accepted: October 28, 2021.
Pre-published: November 4, 2021.
Disclosures: no conflicts of interest to disclose.
Contributions: PM and NS conceived and led the project; NS conducted database building, extraction and coding; NS, PM, PS and ST queried and analyzed the data; PM and NS wrote the main manuscript text and created all tables. All authors made a substantial intellectual contribution to the study, interpreted the data, discussed the results and reviewed, edited and approved the final version of the manuscript.
References
1. Chari A, Samur MK, Martinez-Lopez J, et al. Clinical features asso- ciated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood. 2020;136(26):3033-3040.
2. Martínez-López J, Mateos MV, Encinas C, et al. Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic
factors of inpatient mortality. Blood Cancer J. 2020;10(10):103.
3. Engelhardt M, Shoumariyeh K, Rösner A, et al. Clinical characteris- tics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany.
Haematologica. 2020;105(12):2872-2878.
4. Gonzalez-Lugo JD, Bachier-Rodriguez L, Goldfinger M, et al. A case
series of monoclonal gammopathy of undetermined significance
and COVID-19. Br J Haematol. 2020;190(3):e130-e133.
5. Kyle RA, Larson DR, Therneau TM, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J
Med. 2018;378(3):241-249.
6. van de Donk NW, Palumbo A, Johnsen HE, et al. The clinical rele-
vance and management of monoclonal gammopathy of undeter- mined significance and related disorders: recommendations from the European Myeloma Network. Haematologica. 2014;99(6):984- 996.
7. Kristinsson SY, Björkholm M, Andersson TM, et al. Patterns of sur- vival and causes of death following a diagnosis of monoclonal gam- mopathy of undetermined significance: a population-based study. Haematologica. 2009;94(12):1714-1720.
8. Kristinsson SY,Tang M, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance and risk of infections: a population- based study. Haematologica. 2012;97(6):854-858.
9. G. Onder, G. Rezza, S. Brusaferro. Case-fatality rate and character- istics of patients dying in relation to COVID-19 in Italy. JAMA. 2020;323(18):1775-1776.
10. Lee H, Tay J, Street L, Duggan P, Jiménez-Zepeda VH. Monoclonal gammopathy of undetermined significance clinic during the coron- avirus disease-19 pandemic: caring for the vulnerable in an academic medical center. Rev Invest Clin. 2021;73(4):259-264.
11. Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, et al. The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti- myeloma treatment. Blood Cancer J. 2021;11(8):138.
12. https://cms.cws.net/content/beta.myelomasociety.org/files/PM%2 0COVID%20vaccination%20in%20MM%20guidelines%20The% 20Final.pdf
13. Ludwig H, Meckl A, Engelhardt M. Compliance with vaccination recommendations among patients with multiple myeloma: a real world experience. Hemasphere. 2021;5(7):e597.
14. Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E, Terpos E, Dimopoulos MA. SARS-CoV-2 vaccines in patients with multiple myeloma. Hemasphere. 2021;5(3):e547.
15. Quinn SJ, Anderson LA, Lohfeld L, McShane CM. The psychosocial impact of the COVID-19 pandemic on patients with monoclonal gammopathy of undermined significance, smouldering and active myeloma: findings from an international survey. Br J Haematol. 2021;194(2):294-297.
haematologica | 2022; 107(2)
557